Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the
feasibility and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and
cadonilimab as conversion therapy for unresectable hepatocellular carcinoma.